{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:16:41Z","timestamp":1792430201333,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier","isbn-type":[{"value":"9780128029787","type":"print"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/bs.irn.2015.02.009","type":"book-chapter","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T10:38:37Z","timestamp":1429007917000},"page":"273-300","source":"Crossref","is-referenced-by-count":59,"title":["\u201cLegal Highs\u201d \u2013 An Emerging Epidemic of Novel Psychoactive Substances"],"prefix":"10.1016","author":[{"given":"Jolanta B.","family":"Zawilska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.irn.2015.02.009_bb0005","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/adb.12038","article-title":"Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats","volume":"18","author":"Aarde","year":"2013","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuropharm.2013.04.003","article-title":"The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats","volume":"71","author":"Aarde","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb9000","series-title":"\u201cNBOMe\u201d compounds: a review of the evidence of use and harm","author":"Advisory Council on the Misuse of Drugs (ACMD)","year":"2013"},{"key":"10.1016\/bs.irn.2015.02.009_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.forsciint.2009.01.015","article-title":"Pharmacokinetics of \u2018party pill\u2019 N-benzylpiperazine (BZP) in healthy human participants","volume":"186","author":"Antia","year":"2009","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2015.02.009_bb0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1211\/jpp\/61.07.0006","article-title":"Metabolic interactions with piperazine-based \u2018party pills\u2019","volume":"61","author":"Antia","year":"2009","journal-title":"Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0025","article-title":"Raising awareness of new psychoactive substances: Chemical analysis and in vitro toxicity screening of \u2018legal high\u2019 packages containing synthetic cathinones","author":"Ara\u00fajo","year":"2014","journal-title":"Archives of Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0376-8716(99)00152-0","article-title":"Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding","volume":"60","author":"Aung","year":"2000","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0035","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"\u2018Spice\u2019 and other herbal blends: Harmless incense or cannabinoid designer drugs?","volume":"44","author":"Auw\u00e4rter","year":"2009","journal-title":"Journal of Mass Spectrometry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1465-3362.2012.00519.x","article-title":"Patterns of synthetic cannabinoid use in Australia","volume":"32","author":"Barratt","year":"2013","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/bs.irn.2015.02.009_bb0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/npp.2012.204","article-title":"Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive \u2018bath salts\u2019 products","volume":"38","author":"Baumann","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0050","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/08897077.2011.637610","article-title":"Spice: A new \u201clegal\u201d herbal mixture abused by young active duty military personel","volume":"33","author":"Bebarta","year":"2012","journal-title":"Substance Abuse"},{"key":"10.1016\/bs.irn.2015.02.009_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.drugalcdep.2014.07.009","article-title":"Synthetic cannabinoid use among patients in residential substance use disorder treatment: Prevalence, motives, and correlates","volume":"143","author":"Bonar","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s13181-013-0287-x","article-title":"Recurrent seizures and serotonin syndrome following \u201c2C-I\u201d ingestion","volume":"9","author":"Bosak","year":"2013","journal-title":"Journal of Medical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drugalcdep.2006.10.016","article-title":"Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA)","volume":"88","author":"Brennan","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0070","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bcp.2012.01.004","article-title":"Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity","volume":"83","author":"Brents","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0075","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/0269881110378370","article-title":"Instability of the ecstasy market and a new kid on the block: Mephedrone","volume":"25","author":"Brunt","year":"2011","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7517-4-18","article-title":"Highs and lows: Patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand","volume":"4","author":"Buttler","year":"2007","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/bs.irn.2015.02.009_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1749-6632.2011.06199.x","article-title":"Designer drugs: A medicinal chemistry perspective","volume":"1248","author":"Carroll","year":"2012","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2015.02.009_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0095","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.forsciint.2013.06.007","article-title":"Increases in use of novel synthetic stimulant are not directly linked to decreased use of 3,5-methylenedioxy-N-\u200amethylamphetamine (MDMA)","volume":"231","author":"Chen","year":"2013","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2015.02.009_bb0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.toxlet.2013.01.008","article-title":"5-Iodo-2-aminoindan (5-IAI): Chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects","volume":"218","author":"Coppola","year":"2013","journal-title":"Toxicology Letters"},{"key":"10.1016\/bs.irn.2015.02.009_bb0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drugpo.2012.06.005","article-title":"\u2018Legal highs\u2019 an inappropriate term for 'Novel Psychoactive Drugs' in drug prevention and scientific debate","volume":"24","author":"Corazza","year":"2013","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/bs.irn.2015.02.009_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2014.944291","article-title":"\u201cSpice,\u201d \u201ckryptonite,\u201d \u201cblack mamba\u201d: An overview of brand names and marketing strategies of novel psychoactive substances on the web","volume":"46","author":"Corazza","year":"2014","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2015.02.009_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pnpbp.2012.05.021","article-title":"2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review","volume":"39","author":"Corkery","year":"2012","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/hup.2298","article-title":"MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; \u2018sparkle\u2019; \u2018mindy\u2019) toxicity: A brief overview and update","volume":"28","author":"Corkery","year":"2013","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/bs.irn.2015.02.009_bb0130","first-page":"355","article-title":"Mephedrone-related fatalities in the United Kingdom: Contextual, clinical and practical issues","volume":"17","author":"Corkery","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jat\/bks094","article-title":"Mephedrone (methylmethcathinone) in toxicology casework: A Northern Ireland perspective","volume":"37","author":"Cosbey","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or not 2C: Phenethylamine designer drug review","volume":"9","author":"Dean","year":"2013","journal-title":"Journal of Medical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pnpbp.2012.07.011","article-title":"Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project","volume":"39","author":"Deluca","year":"2012","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0150","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.bjps.2011.10.004","article-title":"The untold truth about \u201cbath salt\u201d highs: A case series demonstrating local tissue injury","volume":"65","author":"Dorairaj","year":"2012","journal-title":"Journal of Plastic, Reconstructive & Aesthetic Surgery"},{"key":"10.1016\/bs.irn.2015.02.009_bb0155","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1556-4029.2009.01199.x","article-title":"Morbidity involving the hallucinogenic designer amines MDA and 2C-I","volume":"54","author":"Drees","year":"2009","journal-title":"Journal of Forensic Sciences"},{"key":"10.1016\/bs.irn.2015.02.009_bb0160","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jms.1811","article-title":"Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds","volume":"45","author":"Dresen","year":"2010","journal-title":"Journal of Mass Spectrometry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.forsciint.2014.04.017","article-title":"A 3-year review of new psychoactive substances in casework","volume":"243","author":"Elliott","year":"2014","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2015.02.009_bb0170","series-title":"Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances","author":"EMCDDA","year":"2011"},{"key":"10.1016\/bs.irn.2015.02.009_bb0175","series-title":"Annual report 2012. The state of the drug problem in Europe","author":"EMCDDA","year":"2012"},{"key":"10.1016\/bs.irn.2015.02.009_bb0180","series-title":"EU drug markets reports. A strategic analysis","author":"EMCDDA","year":"2013"},{"key":"10.1016\/bs.irn.2015.02.009_bb0185","series-title":"European drug report 2014. Trends and developments","author":"EMCDDA","year":"2014"},{"key":"10.1016\/bs.irn.2015.02.009_bb0190","series-title":"EMCDDA\u2014Europol joint report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone)","author":"EMCDDA","year":"2014"},{"key":"10.1016\/bs.irn.2015.02.009_bb0195","series-title":"EMCDDA\u2014Europol joint report on a new psychoactive substance: 5-(2-aminopropyl)indole","author":"EMCDDA","year":"2014"},{"key":"10.1016\/bs.irn.2015.02.009_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to \u03949-THC: Mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2015.02.009_bb0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.drugalcdep.2004.07.014","article-title":"Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys","volume":"77","author":"Fantegrossi","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnbeh.2011.00060","article-title":"Beyond THC: The new generation of cannabinoid designer drugs","volume":"5","author":"Fattore","year":"2011","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/bs.irn.2015.02.009_bb0215","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0960327111421945","article-title":"Synthetic cannabinoid and marijuana exposures reported to poison centers","volume":"31","author":"Forrester","year":"2012","journal-title":"Human & Experimental Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hup.1255","article-title":"5,6-Methylenedioxy-2-aminoindane: From laboratory curiosity to \u2018legal high\u2019","volume":"27","author":"Gallagher","year":"2012","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/bs.irn.2015.02.009_bb0225","first-page":"U1784","article-title":"Toxic effects of BZP-based herbal party pills in humans: A prospective in Christchurch, New Zealand","volume":"118","author":"Gee","year":"2005","journal-title":"New Zealand Medical Journal"},{"key":"10.1016\/bs.irn.2015.02.009_bb0230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/15563650.2011.645952","article-title":"\u2018Legal highs\u2019\u2014Novel and emerging psychoactive drugs: A chemical overview for the toxicologist","volume":"50","author":"Gibbons","year":"2012","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"key":"10.1016\/bs.irn.2015.02.009_bb0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1124\/jpet.111.187757","article-title":"JWH-018 and JWH-073: \u03949-Tetrahydrocannabinol-like discriminative stimulus effects in monkeys","volume":"340","author":"Ginsburg","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2015.02.009_bb0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lfs.2013.10.033","article-title":"Behavioral pharmacology of designer cathinones: A review of the preclinical literature","volume":"97","author":"Gregg","year":"2014","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2015.02.009_bb0245","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/08897077.2013.846288","article-title":"A survey of synthetic cannabinoid consumption by current cannabis users","volume":"35","author":"Gunderson","year":"2014","journal-title":"Substance Abuse"},{"key":"10.1016\/bs.irn.2015.02.009_bb0250","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1373\/clinchem.2012.194381","article-title":"Cannabis effects on driving skills","volume":"59","author":"Hartman","year":"2013","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.forsciint.2014.02.022","article-title":"Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project","volume":"243","author":"Helander","year":"2014","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2015.02.009_bb0260","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/jat\/bks066","article-title":"Prevalence of synthetic cannabinoids in US athletes: Initial findings","volume":"36","author":"Heltsley","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1747-597X-6-16","article-title":"College students and use of K2: An emerging drug of abuse in young persons","volume":"6","author":"Hu","year":"2011","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/bs.irn.2015.02.009_bb0270","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/dta.268","article-title":"The emergence and analysis of synthetic cannabinoids","volume":"3","author":"Hudson","year":"2011","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0275","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/postgradmedj-2012-131428","article-title":"Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM","volume":"90","author":"Hunter","year":"2014","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/bs.irn.2015.02.009_bb0280","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/02791072.2014.962717","article-title":"Investigation of \u201cBath Salts\u201d use pattern within an online sample of users in the United States","volume":"46","author":"Johnson","year":"2014","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2015.02.009_bb0285","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jemermed.2012.09.147","article-title":"Current \u201cLegal highs\u201d","volume":"44","author":"Johnson","year":"2013","journal-title":"Journal of Emergency Medicine"},{"key":"10.1016\/bs.irn.2015.02.009_bb0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/dar.12136","article-title":"5-(2-aminopropyl)indole: A new player in the drama of \u2018legal highs' alerts the community","volume":"34","author":"Katselou","year":"2014","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/bs.irn.2015.02.009_bb0295","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/dta.1570","article-title":"New phenethylamines in Europe","volume":"6","author":"King","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0300","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jat\/bkt058","article-title":"A cluster of deaths involving 5-(2-aminopropyl)indole (5-IT)","volume":"37","author":"Kronstrand","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0305","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.7205\/MILMED-D-12-00180","article-title":"Spice, bath salts, and the U.S. military: The emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces","volume":"177","author":"Loeffler","year":"2012","journal-title":"Military Medicine"},{"key":"10.1016\/bs.irn.2015.02.009_bb0310","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2013.09.011","article-title":"Psychoactive substances\u2014Some new, some old: A scan of the situation in the U.S","volume":"134","author":"Maxwell","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0315","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugpo.2010.11.001","article-title":"Experiences with mephedrone pre- and post-legislative control: Perceptions of safety and sources of supply","volume":"22","author":"McElrath","year":"2011","journal-title":"International Journal on Drug Policy"},{"key":"10.1016\/bs.irn.2015.02.009_bb0320","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jen.2012.07.025","article-title":"Bath salts: Not as harmless as they sound","volume":"38","author":"McGraw","year":"2012","journal-title":"Journal of Emergency Nursing"},{"key":"10.1016\/bs.irn.2015.02.009_bb0325","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/jms.1859","article-title":"Studies on the metabolism of the \u03b1-pyrrolidinophenone designer drug methylenedioxypyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS","volume":"45","author":"Meyer","year":"2010","journal-title":"Journal of Mass Spectrometry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0330","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/138920010791526042","article-title":"Metabolism of designer drugs of abuse: An updated review","volume":"11","author":"Meyer","year":"2010","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/bs.irn.2015.02.009_bb0335","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jms.2960","article-title":"New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoro-methcathinone: Studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC- high-resolution MS and their detectability in urine","volume":"47","author":"Meyer","year":"2012","journal-title":"Journal of Mass Spectrometry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0340","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00216-010-3636-5","article-title":"Beta-keto amphetamines: Studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry","volume":"397","author":"Meyer","year":"2010","journal-title":"Analytical and Bioanalytical Chemistry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0345","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/dta.158","article-title":"Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls","volume":"3","author":"M\u00f6ller","year":"2011","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0350","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00204-013-1057-x","article-title":"Update on 1-benzylpiperazine (BZP) party pills","volume":"87","author":"Monteiro","year":"2013","journal-title":"Archives of Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0355","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000346678","article-title":"Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine","volume":"19","author":"Moore","year":"2013","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2015.02.009_bb0360","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1369-1600.2011.00384.x","article-title":"Mephedrone (4-methylmethcathinone, \u2018meow'): Acute behavioural effects and distribution of Fos expression in adolescent rats","volume":"17","author":"Motbey","year":"2012","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0365","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"\u201cNot for human consumption\u201d: A review of emerging designer drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/bs.irn.2015.02.009_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00414-013-0864-1","article-title":"Driving under the influence of synthetic cannabinoids (\u201cSpice\u201d): A case series","volume":"128","author":"Musshoff","year":"2014","journal-title":"International Journal of Legal Medicine"},{"key":"10.1016\/bs.irn.2015.02.009_bb0375","first-page":"37","article-title":"Emerging drugs of abuse: Current perspectives on substituted cathinones","volume":"5","author":"Paillet-Loilier","year":"2014","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/bs.irn.2015.02.009_bb0380","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hup.2312","article-title":"\u201cSpiceophrenia\u201d: A systematic overview of \u201cspice\u201d-related psychopathological issues and a case report","volume":"28","author":"Papanti","year":"2013","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1016\/bs.irn.2015.02.009_bb0385","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YCO.0000000000000071","article-title":"Emerging drugs in Europe","volume":"27","author":"Papaseit","year":"2014","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0390","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.112.050880","article-title":"In vitro metabolism and pharmacokinetic studies on methylone","volume":"41","author":"Pedersen","year":"2013","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/bs.irn.2015.02.009_bb0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/dta.1369","article-title":"In vitro metabolism studies on mephedrone and analysis of forensic cases","volume":"5","author":"Pedersen","year":"2013","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/3-540-26573-2_1","article-title":"Pharmacological action of cannabinoids","volume":"168","author":"Pertwee","year":"2005","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0405","first-page":"27","article-title":"Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings","volume":"25","author":"Presley","year":"2013","journal-title":"Forensic Science Review"},{"key":"10.1016\/bs.irn.2015.02.009_bb0410","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/dta.1615","article-title":"Cathinones derivatives-related deaths as exemplified by two fatal cases involving methcathinone with 4-methylmethcathinone and 4-methylethcathinone","volume":"6","author":"Rojek","year":"2014","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0415","first-page":"e124","article-title":"Life-treating necrotizing fasciitis due to \u201cbath salts\u201d injection","volume":"25","author":"Russo","year":"2012","journal-title":"Orthopedics"},{"key":"10.1016\/bs.irn.2015.02.009_bb0420","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/08998280.2012.11928883","article-title":"Fatal toxic leukoencephalopathy secondary to overdose of a new psychoactive designer drug 2C-E (\u201cEurope\u201d)","volume":"25","author":"Sacks","year":"2012","journal-title":"Proceedings (Baylor University. Medical Center)"},{"key":"10.1016\/bs.irn.2015.02.009_bb0425","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00213-010-2070-x","article-title":"Mephedrone (4-methylmethcathinone; \u2018meow meow\u2019): Chemical, pharmacological and clinical issues","volume":"214","author":"Schifano","year":"2011","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/bs.irn.2015.02.009_bb0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jat\/bkt053","article-title":"Four fatalities involving 5-IT","volume":"37","author":"Seetohul","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0435","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.euroneuro.2012.09.005","article-title":"Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat","volume":"23","author":"Shortall","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0440","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0445","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bcp.2014.01.024","article-title":"Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives","volume":"88","author":"Simmler","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7861\/clinmedicine.14-4-409","article-title":"\u2018Designer drugs\u2019: Update on the management of novel psychoactive substance misuse in the acute care setting","volume":"14","author":"Smith","year":"2014","journal-title":"Clinical Medicine"},{"key":"10.1016\/bs.irn.2015.02.009_bb0455","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15563650.2011.590812","article-title":"Clinical experience with analytic confirmation of \u201cbath salts\u201d and \u201clegal highs\u201d (synthetic cathinones) in the United States","volume":"49","author":"Spiller","year":"2011","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"key":"10.1016\/bs.irn.2015.02.009_bb0460","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/rcm.4692","article-title":"Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography\/mass spectrometry and liquid chromatography\/quadrupole time-of-flight mass spectrometry","volume":"24","author":"Strano-Rossi","year":"2010","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0465","first-page":"6","article-title":"Sexualised drug use by MSM: Background, current status and response","volume":"13","author":"Stuart","year":"2013","journal-title":"HIV Nursing Journal"},{"key":"10.1016\/bs.irn.2015.02.009_bb0470","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2014.03.003","article-title":"Seizures associated with synthetic cathinone exposures in the pediatric population","volume":"51","author":"Tekulve","year":"2014","journal-title":"Pediatric Neurology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0475","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.jchromb.2010.03.016","article-title":"Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry","volume":"878","author":"Teske","year":"2010","journal-title":"Journal of Chromatography B"},{"key":"10.1016\/bs.irn.2015.02.009_bb0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.aap.2013.09.009","article-title":"Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period","volume":"62","author":"Tuv","year":"2014","journal-title":"Accident Analysis and Prevention"},{"key":"10.1016\/bs.irn.2015.02.009_bb0485","unstructured":"United Nations Office on Drugs and Crime (UNODC). (2013). Worlds drug report 2013. New psychoactive substances: Concepts and definitions, Vienna, pp. 60\u2013115. Available at: http:\/\/www.unodc.org\/unodc\/secured\/wdr\/wdr2013\/World_Drug_Report_2013.pdf. Accessed September 22, 2014."},{"key":"10.1016\/bs.irn.2015.02.009_bb0490","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugpo.2012.01.008","article-title":"\u201cA costly turn on\u201d: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors","volume":"23","author":"Van Hout","year":"2012","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/bs.irn.2015.02.009_bb0495","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","article-title":"A survey study to characterize use of Spice products (synthetic cannabinoids)","volume":"120","author":"Vandrey","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0500","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2009.05.010","article-title":"Discriminative stimulus properties of \u03949-tetrahydrocannabinol (THC) in C57Bl\/6J mice","volume":"615","author":"Vann","year":"2009","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0505","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.toxlet.2010.06.002","article-title":"Spice drugs as a new trend: Mode of action, identification and legislation","volume":"197","author":"Vardakou","year":"2010","journal-title":"Toxicology Letters"},{"key":"10.1016\/bs.irn.2015.02.009_bb0515","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/FBP.0b013e3283641ec8","article-title":"Abuse liability of novel \u2018legal high' designer stimulants: Evidence from animal models","volume":"24","author":"Watterson","year":"2013","journal-title":"Behavioral Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0520","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.drugalcdep.2012.05.034","article-title":"Inhalation exposure to smoke from synthetic \u201cmarijuana\u201d produces potent cannabimimetic effects in mice","volume":"126","author":"Wiebelhaus","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0525","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","article-title":"Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids","volume":"97","author":"Wiley","year":"2014","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2015.02.009_bb0530","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugalcdep.2012.12.011","article-title":"Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample","volume":"131","author":"Winstock","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2015.02.009_bb0535","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF03161209","article-title":"Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 1-benzylpiperazine (BZP)","volume":"4","author":"Wood","year":"2008","journal-title":"Journal of Medical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0540","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/15563650.2012.716158","article-title":"Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP)","volume":"50","author":"Wood","year":"2012","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"key":"10.1016\/bs.irn.2015.02.009_bb0545","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00228-011-1142-0","article-title":"A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity","volume":"68","author":"Wood","year":"2012","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0550","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pbb.2007.06.007","article-title":"MDMA-like behavioral effects of N-substituted piperazines in the mouse","volume":"88","author":"Yarosh","year":"2007","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/bs.irn.2015.02.009_bb0555","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jat\/bkt065","article-title":"Blood synthetic cannabinoid concentrations in cases of suspected impaired driving","volume":"37","author":"Yeakel","year":"2013","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0560","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1874473711104020122","article-title":"\u201cLegal highs\u201d\u2014New players in the old drama","volume":"4","author":"Zawilska","year":"2011","journal-title":"Current Drug Abuse Reviews"},{"key":"10.1016\/bs.irn.2015.02.009_bb0565","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/YCO.0000000000000066","article-title":"Mephedrone and other cathinones","volume":"27","author":"Zawilska","year":"2014","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/bs.irn.2015.02.009_bb0570","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.forsciint.2013.04.015","article-title":"Designer cathinones\u2014An emerging class of novel recreational drugs","volume":"231","author":"Zawilska","year":"2013","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2015.02.009_bb0575","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1017\/S1461145713001247","article-title":"Spice\/K2 drugs: More than innocent substitutes for marijuana","volume":"17","author":"Zawilska","year":"2014","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2015.02.009_bb0580","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/dta.1365","article-title":"Prevalence and co-existence of active components of \u2018legal highs'","volume":"5","author":"Zuba","year":"2013","journal-title":"Drug Testing and Analysis"},{"key":"10.1016\/bs.irn.2015.02.009_bb0585","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00216-011-4743-7","article-title":"Comparison of \u201cherbal highs\u201d composition","volume":"400","author":"Zuba","year":"2011","journal-title":"Analytical and Bioanalytical Chemistry"}],"container-title":["International Review of Neurobiology","The Neuropsychiatric Complications of Stimulant Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774215000124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774215000124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T01:50:12Z","timestamp":1651715412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774215000124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9780128029787"],"references-count":116,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2015.02.009","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}